Disparate evolution of virus populations in upper and lower airways of mechanically ventilated patients.

Björn F. Koel^{1*}, Frank van Someren Gréve¹, René M. Vigeveno¹, Maarten Pater¹, Colin A. Russell¹, Menno D. de Jong¹

¹Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

* Correspondence: b.f.koel@amc.uva.nl

Running title: Distinct virus populations in human upper and lower airways.

Abstract

In routine surveillance and diagnostic testing, influenza virus samples are typically collected only from the upper respiratory tract (URT) due to the invasiveness of sample collection from the lower airways. Very little is known about virus variation in the lower respiratory tract (LRT) and it remains unclear if the virus populations at different sites of the human airways may develop to have divergent genetic signatures. We used deep sequencing of serially obtained matched nasopharyngeal swabs and endotracheal aspirates from four mechanically ventilated patients with influenza A/H3N2 infections. A physical barrier separating both compartments of the respiratory tract introduced as part of the medical procedures enabled us to track and compare the genetic composition of the virus populations during isolated evolution in the same host. Amino acid variants reaching majority proportions emerged during the course of infection in both nasopharyngeal swabs and endotracheal aspirates, and amino acid variation was observed in all influenza virus proteins. Genetic variation of the virus populations differed between the URT and LRT and variants were frequently uniquely present in either URT or LRT virus populations of a patient. These observations indicate that virus populations in spatially distinct parts of the human airways may follow different evolutionary trajectories. Selectively sampling from the URT may therefore fail to detect potentially important emerging variants.

Importance

Influenza viruses are rapidly mutating pathogens that easily adapt to changing environments. Although advances in sequencing technology make it possible to identify virus variants at very low proportions of the within-host virus population, several aspects of intrahost viral evolution have not been studied because sequentially collected samples and samples from the lower respiratory tract are not routinely obtained for influenza surveillance or clinical diagnostic purposes. Importantly, how virus populations evolve in different parts of the human respiratory tract remains unknown. Here we used serial clinical specimens collected from mechanically ventilated influenza patients to compare how virus populations develop in the upper and lower respiratory tract. We show that virus populations in the upper and lower respiratory tract may evolve along distinct evolutionary pathways, and that current sampling and surveillance regimens likely capture only part of the complete intrahost virus variation.

Introduction

Influenza A viruses are genetically variable due to the low fidelity of the influenza virus RNA polymerase and can therefore quickly evolve in response to changing environments and selection pressures, leading to escape from natural or vaccine-induced immunity, antiviral drug resistance and adaptation to new hosts. Intrahost influenza virus populations are genetically heterogeneous and consist of closely related but diverse virus variants. The evolution of influenza viruses has been studied in much detail at population levels on a global scale, but the intrahost evolutionary processes that are fundamental to emergence of new variants in the human population are less well understood.

Influenza viruses can infect and replicate in epithelial cells throughout the upper (URT) and lower respiratory tract (LRT) (1, 2). Differences between cell types and receptor distribution along the respiratory tract, as well as local conditions such as temperature and immunity, may favor the emergence of different variants in different compartments of the human airways. Recent studies indeed suggest compartmentalization of seasonal influenza viruses in the URT and LRT. Richard *et al.* reported that intranasal and intratracheal co-inoculation of ferrets resulted in minimal reassortment of the inoculated viruses (3), and Yan *et al.* found that URT and LRT infections appeared to behave as independent virus populations based on aerosol shedding of human volunteers (4). Although these studies provide clues that virus populations in spatially separated compartments of the respiratory tract may evolve independently, current insights into potential differences in genetic composition and evolution of virus populations between URT and LRT compartments remain incomplete.

Improved understanding would ideally require analyses of serial specimens collected in parallel from both respiratory compartments during the course of influenza, the feasibility of which is challenging due to the invasiveness of such sampling. We had an opportunity to perform such analyses in four influenza A/H3N2 virus-infected patients who participated in a study of the prevalence and shedding patterns of respiratory viruses in critically ill patients receiving mechanical ventilation (5, 6). For the purpose of this study, nasopharyngeal specimens and endotracheal aspirates were collected each day from patients while intubated and ventilated. Endotracheal tubes used for mechanical ventilation contain a balloon cuff designed to provide a seal inside the trachea that allows airflow through the tube whilst preventing passage of air or fluids around it. Importantly, this feature allowed analysis of virus populations in upper and lower respiratory tract compartments in isolation. Using a next generation sequencing approach, virus

populations from both compartments were thus characterized over time, providing evidence indicating differences in genetic composition and diversity .

Results

Limited genetic variation in virus populations from nasopharyngeal swabs and endotracheal aspirates

Matched nasopharyngeal swabs (NPS) and endotracheal aspirates (ETA) were collected daily from mechanically ventilated patients in the context of a Dutch multicenter observational clinical study investigating the prevalence and shedding patterns of respiratory viruses in critically ill patients (5, 6). For the current study we selected all patients with laboratory-confirmed influenza A/H3N2 virus infections in whom viral RNA could be detected in paired NPS and ETA specimens during at least 2 consecutive days. In NPS and ETA from the four patients thus included, influenza virus RNA was detected during respectively 3 - 7 days and 3 - 26 days following intubation (Fig. 1, Fig. S1). Whole genome next generation sequencing (NGS) was performed directly on all virus positive samples to quantify the within-host genetic variation and changes in amino acid variant frequency over time. Genomic data of sufficient quality were obtained from 51 samples in total. To limit inclusion of artifactual variants introduced during library preparation or sequencing, variants were only considered for analyses if present in the virus population during multiple days.

There was limited but evident genetic variation in the intrahost virus populations in the four patients. We identified 31 amino acid variants in the NPS and 34 amino acid variants in the ETA collected among the four patients (Fig 2). Variations in NPS occurred on 28 unique amino acid positions on all but the M1 and NP proteins (Fig 2A). In ETA, variants on 26 unique amino acid positions were found and occurred on all but the PA-X, NS2, and PB1-F2 proteins (Fig. 2B). To identify temporal differences in variant proportions, we arbitrarily set a 5% threshold value for what constitutes a substantial variant proportion difference between same-patient NPS or ETA samples. The difference between minimum and maximum variant proportions exceeded this threshold for 20 variants in NPS and 28 variants in the ETA (Figs. 2C and 2D, Figs S2-S5). Changes in variant proportion fluctuated over time. Variant proportion differences of 15 – 20% between consecutive days were observed in all four patients (Figs S2-S5). However, most variants showed short-lived changes in variant proportion, typically reaching 10 - 20% in the virus population. Few variants persisted at low proportions (<10%) for several days or reached proportions above 20%. Four variants reached majority in the virus population (>50%)—HA G5E (NPS, patient X), NS1 H59L (NPS, patient X), NA E76D (NPS, patient Y), and NS1 L185F (ETA,

patient W). However, consistent outgrowth during sampling was observed only for NS1 H59L, whereas the variant proportions of HA G5E and NS1 L185F dropped below the detection limit within days after reaching majority. We could not determine evolutionary patterns for the duration of infection for NA E76D because the coverage of this genetic region was below our inclusion threshold for three out of five days.

Virus populations in nasopharyngeal swabs and endotracheal aspirates are genetically diverse

To determine whether the genetic composition of the virus populations in NPS and ETA was different, we next analyzed variant proportions in time- and patient matched NPS and ETA. For this analysis we included the variants that were detectable during multiple days and where the difference between variant proportions in NPS and ETA exceeded 5%.

Panels A and B of figure 3 show for each of the patients the variants present in NPS and ETA at the first day of sample collection. Variants that met our inclusion criteria and that were unique to either NPS or ETA were observed in all four patients, albeit at moderate proportions. Variants present in both NPS and ETA similarly showed moderate differences in variant proportions between NPS and ETA samples. Because our analysis of temporal differences in variant proportion indicated that the virus populations in these patients evolved over time, we repeated the analysis using for each patient the samples collected at the last time point where influenza virus-positive NPS and ETA were available (Fig. 3 panels C and D). Also here, variant proportions in the NPS and ETA were genetically different in all patients, and included variants that were present in only one airway compartment. These results show that the genetic composition of the virus populations in NPS and ETA was different during identical periods after intubation in all four patients.

The analysis of differences between the virus populations in NPS and ETA revealed a number of notable variants. Two of the four variants that reach majority proportions, HA G5E and NA E76D, were uniquely observed in the NPS of patients X and Y, respectively (Figs. S3 and S4). The remaining two variants that reach majority proportions, NS1 H59L and NS1 L185F, reach peak variant proportions while being undetectable in the other airway compartment at matched time points. In addition, these variants were present and continued to vary in proportion in ETA after the virus became undetectable in NPS, as was also the case for HA N144K (Fig. 4, and Figs. S2 and S3). Finally, a variant with a truncation of the M2 cytoplasmic tail, M2 R77stop, was observed

in all four patients and was absent only from NPS from patient Y (Figs. S2-S5). Variant proportions of M2 R77stop were mostly different between same-patient time-matched NPS and ETA samples. Like the variants outlined in Fig 4, M2 R77Stop remained present and reached high variant proportions in ETA samples of patients W and X after NPS samples became virus negative.

Discussion

Meaningfully studying intrahost genetic variation of human influenza A virus populations has become possible in the past few years as a result of progress in sequencing technologies. Multiple groups have now used deep sequencing approaches to determine the genetic variation of human influenza A viruses in patient-derived materials. These studies have mostly focused on variation in relation to immune escape because of the major role of this process in influenza virus evolution (7–9), or on better understanding transmission bottlenecks and stringency of intrahost selection pressures (10–12). The scarcity of sequentially collected clinical specimens accessible for scientific purposes, particularly those obtained from the lower respiratory tract, has limited the opportunities for studying the temporal genetic variation of within-host influenza virus populations (9, 13, 14). Here we had the opportunity to study intrahost viral genetic variation in longitudinally collected nasopharyngeal swabs and endotracheal aspirates of individuals in whom upper and lower airway compartments were separated by a physical barrier due to mechanical ventilation. We evaluated the intrahost evolutionary patterns of influenza A/H3N2 virus in both airway compartments and compared the genetic composition of the virus populations in the upper and lower airways .

Our results indicate intrahost viral genetic diversity and temporal differences in the composition of the virus populations in the URT and in the LRT of all patients. The modest number of variants observed in each patient is in concordance with previous studies that reported limited genetic variation based on studies using single time points (7, 8, 10). Nonetheless, we observed outgrowth of several variants towards or above majority proportions, often reaching peak proportions within a week after the start of sample collection. Our data also point out that variants may reach majority proportions in both airway compartments. These outcomes suggest that substantial genetic changes in the influenza A virus populations of the URT and LRT can take place during the short time periods typical of transient influenza virus infections.

The different variants and variant proportions detected in URT and LRT samples indicates that genetically related but distinct virus populations existed in the upper and lower airway

compartments of the patients included in this study. Our finding that distinct viral genotypes frequently existed in one but not the other airway compartment complements a recent study that demonstrated spatial separation of the virus populations in humans without the mechanical barrier that was present in the patients sampled for the current study (4). That work showed that humans generate infectious aerosols that represent infection of the LRT and that viral load in URT samples poorly predicted shedding of virus in aerosols. Here we show that virus populations in distal parts of the human airways were composed of distinct viral genotypes that followed isolated evolutionary pathways. If aerosols support influenza virus transmission, the results of the current study imply that variants originating from the lower airways may contribute to long-term (interhost) virus evolution. The differences between genetic compositions of virus populations in the URT and LRT, even during matched time points, suggests that genetic analysis of the virus population in URT samples is a poor proxy for genetic variation in the LRT virus population. Given that current sampling regimens rarely include sample collection from the LRT, a potentially important evolutionary setting may be almost entirely unexplored.

While it is plausible that the distinct physiological conditions and receptor distributions in the URT and LRT gives rise to site specific variants, identification of adaptive amino acid changes resulting from selection pressures specific to either compartment was precluded by the limited number of patients in this study. However, HA N144K, HA R229K, NA V251I, and NS1 L185F have been associated with antibody evasion or immune modulation (15–20), which may explain the rapid increase in variant proportion of some of these variants. Our findings are in agreement with previous results that reported limited variation on amino acid positions associated with immune escape (7–9, 12), and studies that suggested that antigenic adaptation is unlikely to be a major mechanism responsible for intrahost genetic variation (8). Additionally, truncation of M2 at position 77 was shown to have no impact on ion-channel activity (21), suggesting that this amino acid variation may also have been phenotypically neutral in the viruses observed in this study. The phenotypic effects of other notable variants, including those reaching majority proportions, have to our knowledge not been reported.

In summary, we showed disparate evolution of virus populations in spatially separated parts of the human airways following natural infection with a seasonal human influenza virus. The temporal variability and genetic differences between intrahost virus populations puts into question the significance of samples collected at a single site or at a single time point. Timing, duration, and site of sample collection are critical variables that could affect the outcomes of influenza

surveillance, and of studies into influenza disease and virus evolution. This is especially true for studies looking into intrahost genetic diversity using deep sequencing approaches.

Materials and Methods

Patients and samples

The samples used in this study were collected as part of a multicenter prospective observational study performed in The Netherlands (Dutch Trial Register NTR4102) as described previously (22). A waiver from the Medical Research Involving Humans Act was provided by the Institutional Review Board of the Academic Medical Center, Amsterdam, due to non-invasiveness of study procedures. Patients and/or their legal representatives were provided with written study information at ICU admission, and could opt-out of the study participation. Included were critically ill patients requiring intubation and mechanical ventilation, admitted to the participating ICUs between April 2013 and April 2014. Daily nasopharyngeal NPS and tracheobronchial ETA were collected until detubation or death while on mechanical ventilation. All samples obtained upon admission were tested with a validated multiplex RT-PCR for respiratory viruses, as previously described (23, 24). For the current study, all patients that were influenza A/H3N2 virus positive for multiple days positive were included. Intubation and sampling of patients X,Y, and Z started at the day of admission to the ICU. Patient W had been admitted to the ICU for 6 days prior to the start of intubation and sampling. Patient characteristics are available from Table S1. Viral loads for all patients and time points are indicated in figure S1.

Library preparation and deep sequencing

Total RNA was extracted from the clinical specimens using the High Pure RNA isolation kit (Roche, 11828665001) according to manufacturer's instructions. Influenza RNAs were reverse transcribed and amplified using the superscript III One-Step RT PCR Platinum Taq High Fidelity DNA Polymerase (ThermoFisher, 12574030) and A(H3N2) virus subtype and gene segment specific primers (Table S3). For whole genome amplification we performed 20 independent PCR reactions in total. Three partly overlapping amplicons were generated for the PB2, PB1, PA, HA, NA and NP segments each, a single amplicon each was generated for the M and NS gene segments. For each sample, PCR products were pooled in equimolar concentrations and subsequently purified using Agencourt Ampure XP beads (Beckman Coulter, A63882) and quantified using the Qubit dsDNA HS assay kit (ThermoFisher, Q32854). Pooled and cleaned amplicons were diluted to 0.2 ng/μl for subsequent library preparation.

Sequencing libraries were prepared using the Nextera XT DNA Library Preparation kit (Illumina, FC-131-1096) according to manufacturer's instructions. Briefly, for each sample 5 µl of diluted amplicons were enzymatically fragmented and Illumina adapters were ligated to the fragments. Subsequently each sample was purified twice using Agencourt Ampure XP beads. Library size distribution was evaluated using the High sensitivity dsDNA kit on a 2100 Bioanalyzer (Agilent, 5067-4626) and qPCR based library quantification was performed using the KAPA Library Quantification kit for Illumina platforms (KAPA Biosystems, KK4824) on a LightCycler480 (Roche). Normalized library pools were sequenced on an Illumina MiSeq machine using the 600-cycle MiSeq Reagent Kit v3 (Illumina, MS-102-3003). All FASTQ files are available on request.

Quality control, variant detection and data analysis

Quality trimming of Illumina MiSeq reads was performed using the Maximum Information quality filtering approach of the Trimmomatic tool (version 0.36, parameters; leading:3, trailing:3, maxinfo: 80:0.4, crop:280) (25). Merging, mapping, and coverage analysis was done using the BBmerge, BBwrap, and pileup scripts from the BBMap bioinformatics toolkit version 36.27 (26). Read pairs with inappropriate orientation and reads with a Q-score below 25 were discarded. Quality control was monitored using FastQC version v0.11.5 (27).

Subsequent steps were performed using a set of custom scripts (available on request). Mapped reads were translated and prepared for variant calling by identification of appropriate reading frames and conversion of read numbering to protein numbering for the 12 influenza A virus proteins considered here; PB2 (polymerase basic 2), PB1 (polymerase basic 1), PA (polymerase acidic), HA (hemagglutinin), NP (nucleoprotein), NA (neuraminidase), M1 (matrix protein 1), PA-X (polymerase acidic protein-X), NS1 (non-structural protein 1), NS2 (nuclear export protein), M2 (matrix 2 ion channel), and PB1-F2 (PB1 frame 2). HA amino acid positions in the manuscript are numbered according to Burke *et al.* (28). For each patient the data on coverage per position, variant count, and variant proportion was collected for all time points and for URT and LRT samples. Next a number of filtering steps was performed. Variants passing filter were outside of primer regions, had a minimum coverage of 100x for each position in the codon, and were present at at least 1% of the total virus population with a minimum of five observations per sample. All variants included in our analyses were detectable in two or more samples from the same airway compartment and reached a variant proportion of at least 5%. Variants identified in the overlapping regions of the PA gene products (PA and PA-X), M gene products (M1 and M2), and NS gene products (NS1 and NS2) were called independently.

249

250 **Acknowledgements**

251 This research was supported by ZonMW TOP grant and a Postdoc Stipend of the Amsterdam
252 Infection and Immunity Institute. The authors are grateful to Sylvie Koekkoek, Silvana Roos,
253 Matthijs Welkers, Dirk Eggink, Nicole Juffermans, and Marcus Schultz from the AMC Amsterdam,
254 The Netherlands, and to Frank Harders from the Central Veterinary Institute, The Netherlands, for
255 assistance and technical support. BFK and MP thank SURFsara (www.surfsara.nl) for the support
256 in using the Lisa Compute Cluster.

1. Van Riel D, Munster VJ, De Wit E, Rimmelzwaan GF, Fouchier RAM, Osterhaus ADME, Kuiken T. 2007. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. *Am J Pathol* 171:1215–1223.
2. Chutinimitkul S, van Riel D, Munster VJ, van den Brand JMA, Rimmelzwaan GF, Kuiken T, Osterhaus ADME, Fouchier RAM, de Wit E. 2010. In Vitro Assessment of Attachment Pattern and Replication Efficiency of H5N1 Influenza A Viruses with Altered Receptor Specificity. *J Virol* 84:6825–6833.
3. Richard M, Herfst S, Tao H, Jacobs NT, Lowen AC. 2017. Influenza A virus reassortment is limited by anatomical compartmentalization following co-infection via distinct routes. *J Virol* JVI.02063-17.
4. Yan J, Grantham M, Pantelic J, Bueno de Mesquita PJ, Albert B, Liu F, Ehrman S, Milton DK. 2018. Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community. *Proc Natl Acad Sci* 115:1081–1086.
5. van Someren Gréve F, Ong DSY, Cremer OL, Bonten MJM, Bos LDJ, de Jong MD, Schultz MJ, Juffermans NP. 2016. Clinical practice of respiratory virus diagnostics in critically ill patients with a suspected pneumonia: A prospective observational study. *J Clin Virol* 83:37–42.
6. Van Someren Gréve F, Juffermans NP, Bos LDJ, Binnekade JM, Braber A, Cremer OL, De Jonge E, Molenkamp R, Ong DSY, Rebers SPH, Spoelstra-De Man AME, Van Der Sluijs KF, Spronk PE, Verheul KD, De Waard MC, De Wilde RBP, Winters T, De Jong MD, Schultz MJ. 2018. Respiratory Viruses in Invasively Ventilated Critically Ill Patients-A Prospective Multicenter Observational Study. *Crit Care Med* 46:29–36.
7. Dinis JM, Florek NW, Fatola OO, Moncla LH, Mutschler JP, Charlier OK, Meece JK, Belongia EA, Friedrich TC. 2016. Deep Sequencing Reveals Potential Antigenic Variants at Low Frequencies in Influenza A Virus-Infected Humans. *J Virol* 90:3355–3365.
8. Debbink K, McCrone JT, Petrie JG, Truscon R, Johnson E, Mantlo EK, Monto AS, Llaurens AS. 2017. Vaccination has minimal impact on the intrahost diversity of H3N2 influenza viruses. *PLoS Pathog* 13:1–18.
9. Xue KS, Stevens-Ayers T, Campbell AP, Englund JA, Pergam SA, Boeckh M, Bloom JD. 2017. Parallel evolution of influenza across multiple spatiotemporal scales. *Elife* 6:1–16.
10. Sobel Leonard A, McClain MT, Smith GJD, Wentworth DE, Halpin RA, Lin X, Ransier A, Stockwell TB, Das SR, Gilbert AS, Lambkin-Williams R, Ginsburg GS, Woods CW, Koelle K. 2016. Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective Bottleneck and Only Limited Intrahost Genetic Diversification. *J Virol*

90:11247–11258.

11. Poon LLM, Song T, Rosenfeld R, Lin X, Rogers MB, Zhou B, Sebra R, Halpin RA, Guan Y, Twaddle A, DePasse J V., Stockwell TB, Wentworth DE, Holmes EC, Greenbaum B, Peiris JSM, Cowling BJ, Ghedin E. 2016. Quantifying influenza virus diversity and transmission in humans. *Nat Genet* 48:195–200.
12. McCrone JT, Woods RJ, Martin ET, Malosh RE, Monto AS, Llaurens AS. 2018. Stochastic processes constrain the within and between host evolution of influenza virus. *Elife* 7:1–19.
13. Ghedin E, Laplante J, DePasse J, Wentworth DE, Santos RP, Lepow ML, Porter J, Stellrecht K, Lin X, Operario D, Griesemer S, Fitch A, Halpin RA, Stockwell TB, Spiro DJ, Holmes EC, St George K. 2011. Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. *J Infect Dis* 203:168–174.
14. Rogers MB, Song T, Sebra R, Greenbaum BD, Hamelin ME, Fitch A, Twaddle A, Cui L, Holmes EC, Boivin G, Ghedin E. 2015. Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection. *MBio* 6:1–8.
15. Das SR, Hensley SE, Ince WL, Brooke CB, Subba A, Delboy MG, Russ G, Gibbs JS, Bennink JR, Yewdell JW. 2013. Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. *Cell Host Microbe* 13:314–323.
16. Twu KY, Noah DL, Rao P, Kuo R-L, Krug RM. 2006. The CPSF30 Binding Site on the NS1A Protein of Influenza A Virus Is a Potential Antiviral Target. *J Virol* 80:3957–3965.
17. Marc D. 2014. Influenza virus non-structural protein NS1: Interferon antagonism and beyond. *J Gen Virol* 95:2594–2611.
18. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GCM, Vervaet G, Skepner E, Lewis NS, Spronken MIJ, Russell CA, Eropkin MY, Hurt AC, Barr IG, de Jong JC, Rimmelzwaan GF, Osterhaus ADME, Fouchier RAM, Smith DJ. 2013. Substitutions Near the Receptor Binding Site Determine Major Antigenic Change During Influenza Virus Evolution. *Science* (80-) 342:976–979.
19. Venkatramani L, Bochkareva E, Lee JT, Gulati U, Graeme Laver W, Bochkarev A, Air GM. 2006. An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. *J Mol Biol* 356:651–663.
20. Wiley DC, Wilson IA, Skehel JJ. 1981. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation.

Nature 289:373–8.

21. Tobler K, Kelly ML, Pinto LH, Lamb RA. 1999. Effect of cytoplasmic tail truncations on the activity of the M(2) ion channel of influenza A virus. *J Virol* 73:9695–701.
22. Someren Gréve F van, van der Sluijs KF. 2015. Course - Prevalence, Clinical Outcomes and Viral Shedding Patterns during Viral Respiratory Tract Infections in Intubated Intensive Care Unit-patients: Design and Protocol. *J Clin Trials* 04.
23. Jansen RR, Schinkel J, Koekkoek S, Pajkrt D, Beld M, de Jong MD, Molenkamp R. 2011. Development and evaluation of a four-tube real time multiplex PCR assay covering fourteen respiratory viruses, and comparison to its corresponding single target counterparts. *J Clin Virol* 51:179–85.
24. van de Pol AC, van Loon AM, Wolfs TFW, Jansen NJG, Nijhuis M, Breteler EK, Schuurman R, Rossen JWA. 2007. Increased detection of respiratory syncytial virus, influenza viruses, parainfluenza viruses, and adenoviruses with real-time PCR in samples from patients with respiratory symptoms. *J Clin Microbiol* 45:2260–2.
25. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics* 30:2114–2120.
26. BBMap short read aligner, and other bioinformatic tools.
<https://sourceforge.net/projects/bbmap/>.
27. FastQC. <http://www.bioinformatics.babraham.ac.uk/projects/fastqc>.
28. Burke DF, Smith DJ. 2014. A Recommended Numbering Scheme for Influenza A HA Subtypes. *PLoS One* 9:e112302.

FIG 1 Sample overview (A) Samples were collected daily from the nasopharyngeal (red) and bronchotracheal area (blue) and are referred to here as upper and lower respiratory tract samples, respectively. (B) High quality NGS data were obtained from serially collected samples throughout the course of infection of four patients; W, X, Y, and Z. Samples indicated as grey bars were influenza virus negative or NGS data did not pass quality control during analysis. Numbers in the top row of panel B indicate days since intubation. Patient designation, age and admission date are indicated in the figure. An asterisk indicates the days on which antiviral treatment with oseltamivir was administered.

FIG 2 Overview of proteins and amino acid positions responsible for diversity in the virus populations in NPS and ETA. Variants are color coded by patient, patient W; red, patient X; green, patient Y; blue, patient Z; purple. (A) Variable amino acid positions identified in NPS indicated on the A/H3N2 virus proteins. Vertical lines indicate amino acid positions at intervals of 100 amino acids. White vertical bars indicate primer regions. (B) As panel A, but showing the variable amino acid positions identified in ETA. (C) Maximum proportion differences of variants in NPS. X-axis labels indicate protein and amino acid positions. The threshold used in the analysis of temporal variation is indicated as a dashed line. Variants with temporal differences in variant proportion exceeding this threshold are listed in Table 1. (D) As panel B, but showing maximum proportion differences of variants in ETA. A/H3N2 virus HA numbering according to Burke *et al.* (28).

FIG 3 Variant proportions in NPS and ETA at matched time points. Variants are color coded by patient, patient W; red, patient X; green, patient Y; blue, patient Z; purple. Panels (A) and (B) show the variant proportions in NPS and ETA, respectively, at the first day of sample collection. Column headings indicate the proteins in which variation was detected. Variants are labelled by amino acid position. Panels (C) and (D) show the variant proportions of variants in NPS and ETA, respectively, from the last available influenza virus-positive time-matched samples.

FIG 4 Sustained evolution of variants in the LRT. Blue and green filled areas indicate the proportion of the variant in the URT and LRT, respectively. Filled circles represent the samples included in variant analysis; black dots represent samples with variant proportions above the detection limit, grey dots indicate absence of the variant. (A) evolutionary dynamics of NS1 H59L in patient X. (B) evolutionary dynamics of NS1 L185F in patient W. (C) evolutionary dynamics of HA N144K in patient W.

FIG S1 Viral load in NPS (blue) and ETA (green) specimens of patients W, X, Y, and Z. Filled circles indicate high quality samples included in variant analysis.

FIG S2 Evolutionary dynamics of variants showing substantial temporal variation for patient W. Blue on an orange background indicates the proportion of the variant in the URT, green on a brown background indicates the proportion of the variant in the LRT. Filled circles represent the samples included in variant analysis. The protein and variant are indicated in the figures. Capital letters indicate the amino acid that is the majority amino acid on a given position, small letters indicate the minority variant.

FIG S3 Evolutionary dynamics of variants showing substantial temporal variation for patient X. Symbols and colors as in Fig S2.

FIG S4 Evolutionary dynamics of variants showing substantial temporal variation for patient Y. Symbols and colors as in Fig S2.

FIG S5 Evolutionary dynamics of variants showing substantial temporal variation for patient Z. Symbols and colors as in Fig S2.

FIG 1

FIG 2

FIG 3

FIG 4

FIG S1

FIG S2

FIG S3

FIG S4

FIG S5

Table 1. Amino acid variants with temporal differences in variant proportion exceeding 5%.

patient	sample type					
	swabs			aspirates		
W	PB2 482KR	HA I335K	M2 R77stop	PB2 G131V	NP H272C	NA I397Q
	PB1 N382H	NA T365I	M2 N82S	PB2 P132L	NP 273KR	NS1 H59L
	PB1 E383V	NS1 L185F	M2 S89G	PA V421I	NP K293Q	NS1 L185F
				HA N144K	NP E465V	M2 E75R
				HA Y511D	NA V396A	M2 R77stop
				NP R175K		
X	HA G5E	NS1 H59L		PB2 K140I	PB1 D76N	NS1 H59L
	NA V251I	M2 R77stop		PB2 R142F	HA R229K	NS1 W102C
	PA-X T239M			PB2 R251K	HA Y511D	M2 R77stop
				PB2 L317F	NA R288L	
				PB2 R318S	M1 A182T	
Y	PB2 G131V	HA Y511D	NS2 G22R	PB2 K140I		
	PB2 K140I	NA E76D	PB1-F2 W58stop	PB2 R142F		
	PB2 R142F	PA-X V212A		M2 R77stop		
	PB2 K197N	NS1 H59L				
	PB1 L364I	NS1 G179E				
Z	PB1 K577N	HA V429I	M2 R77stop	PB2 R251K		
	PA S632T	HA Y511D		M2 R77stop		

The influenza virus proteins analyzed for this study are basic polymerase 2 (PB2), basic polymerase 1 (PB1), acidic polymerase (PA), hemagglutinin (HA), nucleoprotein (NP), neuraminidase (NA), matrix protein 1 (M1), acidic polymerase protein X (PA-X), non-structural protein 1 and 2 (NS1, NS2), matrix protein 2 (M2), and basic polymerase 1 frame 2 (PB1-F2). A/H3N2 virus HA numbering according to Burke *et al.* (28).

Table S1. Patient characteristics.

	patient W	patient X	patient Y	patient Z
Reason of ICU admission	Severe acute respiratory infection	Severe acute respiratory infection	Respiratory surgery	Severe acute respiratory infection
Comorbidities	none	none	none	DMII, CHF
Age (years)	61	83	59	76
Sex	male	male	female	female
Received oseltamivir	no	no	yes	yes
Clinical parameters (at ICU admission)				
Temperature (°C)	38.9	36.5	36.7	34.3
Leucocytes (10 ⁹ /L)	10,6	12,4	11,9	24,8
CRP (mg/L)	11	37	11	41
Consolidation on chest X-ray	no	no	no	yes
APACHE II score	24	30	14	35
SAPS II	50	55	39	62
Clinical outcomes				
ICU length of stay (days)	37	26	6	4
Hospital length of stay (days)	86	34	13	4
Died during hospital admission	no	yes	no	yes

Abbreviations: APACHE II = Acute Physiology and Chronic Health Evaluation II ; CHF = congestive heart failure; CRP = C-reactive protein; DMII = diabetes mellitus type II; ICU = intensive care unit; SAPS II = Simplified Acute Physiology Score II;